Celgene to buy Juno for $9 billion

Published January 22, 2018 0 Plays

Rumble Celgene announced a $9 billion cash buyout of Juno Therapeutics as it moves to cement its position as a key player in a new range of cancer therapies. Aleksandra Michalska reports.

0 COMMENTS